Mufg Securities Americas Inc. Buys Shares of 5,065 Stryker Co. (NYSE:SYK)

Mufg Securities Americas Inc. acquired a new stake in shares of Stryker Co. (NYSE:SYK - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 5,065 shares of the medical technology company's stock, valued at approximately $1,824,000.

Other large investors also recently modified their holdings of the company. Elefante Mark B bought a new position in shares of Stryker in the 4th quarter worth about $337,000. Chicago Capital LLC lifted its position in shares of Stryker by 3.1% in the 4th quarter. Chicago Capital LLC now owns 195,052 shares of the medical technology company's stock worth $70,228,000 after buying an additional 5,841 shares during the last quarter. Zhang Financial LLC lifted its position in shares of Stryker by 55.0% in the 4th quarter. Zhang Financial LLC now owns 114,889 shares of the medical technology company's stock worth $41,366,000 after buying an additional 40,784 shares during the last quarter. Appleton Partners Inc. MA lifted its position in shares of Stryker by 5.0% in the 4th quarter. Appleton Partners Inc. MA now owns 29,222 shares of the medical technology company's stock worth $10,521,000 after buying an additional 1,400 shares during the last quarter. Finally, Metis Global Partners LLC lifted its position in shares of Stryker by 10.2% in the 4th quarter. Metis Global Partners LLC now owns 16,841 shares of the medical technology company's stock worth $6,064,000 after buying an additional 1,561 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Price Performance

Shares of SYK traded up $2.04 during mid-day trading on Friday, hitting $394.24. The company's stock had a trading volume of 1,113,972 shares, compared to its average volume of 1,346,938. The firm has a 50-day moving average price of $366.62 and a 200 day moving average price of $375.39. The stock has a market capitalization of $150.48 billion, a price-to-earnings ratio of 50.80, a PEG ratio of 2.93 and a beta of 0.93. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to the consensus estimate of $5.68 billion. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The firm's quarterly revenue was up 11.9% compared to the same quarter last year. During the same period last year, the firm posted $2.50 earnings per share. On average, research analysts predict that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Monday, June 30th will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.85%. The ex-dividend date of this dividend is Monday, June 30th. Stryker's dividend payout ratio (DPR) is currently 45.41%.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on SYK shares. The Goldman Sachs Group set a $422.00 price target on shares of Stryker in a research report on Tuesday, March 4th. Canaccord Genuity Group lifted their price objective on shares of Stryker from $420.00 to $435.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Royal Bank of Canada lifted their price objective on shares of Stryker from $425.00 to $435.00 and gave the company an "outperform" rating in a research report on Wednesday, January 29th. Barclays lifted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research report on Monday, February 10th. Finally, Wells Fargo & Company lifted their price objective on shares of Stryker from $427.00 to $435.00 and gave the company an "overweight" rating in a research report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $427.05.

Insider Transactions at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the firm's stock in a transaction that occurred on Tuesday, May 6th. The shares were sold at an average price of $376.96, for a total transaction of $75,392,000.00. Following the completion of the sale, the director now directly owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. This trade represents a 5.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Allan C. Golston sold 2,458 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the sale, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This represents a 14.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.